PET-directed therapy in Hodgkin lymphoma: Ready for prime time?

Timothy H. Dorius, Nathan R. Bennion, James Olen Armitage

Research output: Contribution to journalReview article

Abstract

Advances in chemotherapy and radiation therapy have allowed the vast majority of patients with Hodgkin lymphoma to be cured, but some of these patients develop treatment-related complications, including second malignancies, cardiovascular disease, and thyroid disease. Efforts to decrease exposure of patients to more chemotherapy or radiation therapy than is necessary to cure their disease have led to a trend toward shortened treatment regimens in patients with low-risk disease. Predicting which patients will relapse, and therefore might benefit from a more intense treatment regimen, has been a clinical challenge. PET has emerged as a useful modality in the diagnosis and management of Hodgkin lymphoma, and has been studied as a potential tool to help the oncologist to utilize the optimal chemotherapy and radiation therapy regimen for each patient.

Original languageEnglish (US)
Pages (from-to)1431-1441
Number of pages11
JournalExpert review of anticancer therapy
Volume15
Issue number12
DOIs
StatePublished - Dec 2 2015

Fingerprint

Hodgkin Disease
Radiotherapy
Drug Therapy
Therapeutics
Second Primary Neoplasms
Thyroid Diseases
Cardiovascular Diseases
Recurrence

Keywords

  • BEACOPP
  • FDG-PET
  • Hodgkin lymphoma
  • PET-directed
  • adriamycin
  • bleomycin
  • dacarbazine
  • deauville criteria
  • vinblastine

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Cite this

PET-directed therapy in Hodgkin lymphoma : Ready for prime time? / Dorius, Timothy H.; Bennion, Nathan R.; Armitage, James Olen.

In: Expert review of anticancer therapy, Vol. 15, No. 12, 02.12.2015, p. 1431-1441.

Research output: Contribution to journalReview article

Dorius, Timothy H. ; Bennion, Nathan R. ; Armitage, James Olen. / PET-directed therapy in Hodgkin lymphoma : Ready for prime time?. In: Expert review of anticancer therapy. 2015 ; Vol. 15, No. 12. pp. 1431-1441.
@article{010ac3a226914e6fb1bf5f9093d344ce,
title = "PET-directed therapy in Hodgkin lymphoma: Ready for prime time?",
abstract = "Advances in chemotherapy and radiation therapy have allowed the vast majority of patients with Hodgkin lymphoma to be cured, but some of these patients develop treatment-related complications, including second malignancies, cardiovascular disease, and thyroid disease. Efforts to decrease exposure of patients to more chemotherapy or radiation therapy than is necessary to cure their disease have led to a trend toward shortened treatment regimens in patients with low-risk disease. Predicting which patients will relapse, and therefore might benefit from a more intense treatment regimen, has been a clinical challenge. PET has emerged as a useful modality in the diagnosis and management of Hodgkin lymphoma, and has been studied as a potential tool to help the oncologist to utilize the optimal chemotherapy and radiation therapy regimen for each patient.",
keywords = "BEACOPP, FDG-PET, Hodgkin lymphoma, PET-directed, adriamycin, bleomycin, dacarbazine, deauville criteria, vinblastine",
author = "Dorius, {Timothy H.} and Bennion, {Nathan R.} and Armitage, {James Olen}",
year = "2015",
month = "12",
day = "2",
doi = "10.1586/14737140.2015.1096202",
language = "English (US)",
volume = "15",
pages = "1431--1441",
journal = "Expert Review of Anticancer Therapy",
issn = "1473-7140",
publisher = "Expert Reviews Ltd.",
number = "12",

}

TY - JOUR

T1 - PET-directed therapy in Hodgkin lymphoma

T2 - Ready for prime time?

AU - Dorius, Timothy H.

AU - Bennion, Nathan R.

AU - Armitage, James Olen

PY - 2015/12/2

Y1 - 2015/12/2

N2 - Advances in chemotherapy and radiation therapy have allowed the vast majority of patients with Hodgkin lymphoma to be cured, but some of these patients develop treatment-related complications, including second malignancies, cardiovascular disease, and thyroid disease. Efforts to decrease exposure of patients to more chemotherapy or radiation therapy than is necessary to cure their disease have led to a trend toward shortened treatment regimens in patients with low-risk disease. Predicting which patients will relapse, and therefore might benefit from a more intense treatment regimen, has been a clinical challenge. PET has emerged as a useful modality in the diagnosis and management of Hodgkin lymphoma, and has been studied as a potential tool to help the oncologist to utilize the optimal chemotherapy and radiation therapy regimen for each patient.

AB - Advances in chemotherapy and radiation therapy have allowed the vast majority of patients with Hodgkin lymphoma to be cured, but some of these patients develop treatment-related complications, including second malignancies, cardiovascular disease, and thyroid disease. Efforts to decrease exposure of patients to more chemotherapy or radiation therapy than is necessary to cure their disease have led to a trend toward shortened treatment regimens in patients with low-risk disease. Predicting which patients will relapse, and therefore might benefit from a more intense treatment regimen, has been a clinical challenge. PET has emerged as a useful modality in the diagnosis and management of Hodgkin lymphoma, and has been studied as a potential tool to help the oncologist to utilize the optimal chemotherapy and radiation therapy regimen for each patient.

KW - BEACOPP

KW - FDG-PET

KW - Hodgkin lymphoma

KW - PET-directed

KW - adriamycin

KW - bleomycin

KW - dacarbazine

KW - deauville criteria

KW - vinblastine

UR - http://www.scopus.com/inward/record.url?scp=84949314509&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84949314509&partnerID=8YFLogxK

U2 - 10.1586/14737140.2015.1096202

DO - 10.1586/14737140.2015.1096202

M3 - Review article

C2 - 26472333

AN - SCOPUS:84949314509

VL - 15

SP - 1431

EP - 1441

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

SN - 1473-7140

IS - 12

ER -